Q-omics provides the consensus-scored RIOX2 profile across patient tissues and cancer cell-line models. RIOX2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RIOX2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RIOX2 RNA expression shows 19,243 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where RIOX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIOX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIOX2 survival associations across molecular data types. RIOX2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIOX2 RNA expression–survival associations across cancer types. High RIOX2 expression shows unfavorable associations in KIRP, LIHC, LGG and CESC, but favorable associations in READ and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RIOX2 RNA expression.
This table summarizes RIOX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RIOX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIOX2 shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in COAD, LUAD and LIHC. The KIRC box plot shows higher RIOX2 RNA expression in normal versus tumor tissue (log2 FC = −1.138, t-test p < 0.001).
This table shows molecular features associated with RIOX2 in patient tissues and cancer cell lines. In patient samples, RIOX2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIOX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
